


Obtain Free CE Credits!

ACCP Clinical Practice Webinars

Cytokine Release Syndrome: Implications in Drug Development

Live Session: Thursday, May 29th, 2025, from 12:00 to 1:00 PM ET

On Demand: May 29th, 2025 to May 29th, 2028



Why is this webinar important to you?

Cytokine release syndrome (CRS) is a life-threatening systemic inflammatory syndrome involving elevated levels of circulating cytokines and immune cell hyperactivation that can be triggered by various therapies, pathogens, cancers, autoimmune conditions and monogenic disorders. Many therapeutics such as cancer immunotherapy (CAR-T, CD3 bispecifics, etc.) can lead to CRS. To mitigate the CRS risk, various approaches were investigated in clinical trials, including priming dosing (step-up dosing, split dosing, dose fractionation, etc.) and premedications. Translational modeling approaches such as mechanistic quantitative systems pharmacology models were also developed to optimize the dose in the clinic to minimize the CRS. In addition, CRS could also result in drug-drug interaction (DDI) risks due to the suppression of CYP enzymes and transporters by the proinflammatory cytokines. Physiologically-based pharmacokinetic approaches have been utilized to assess CRS mediated DDI risks. This activity will focus on the current scientific aspects for CRS and its implications in drug development as well as future perspectives. Learners who complete this activity will have enhanced knowledge utilizing case examples and discussions.



ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-25-006-L01-P & 0665-0000-25-006-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Live & Home-study **Target Audience:** 'P'



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of graduate students, postdoctoral fellows/trainees and professionals in the field of pharmacy, pharmacometrics, clinical pharmacology and clinical pharmacy practice. This activity is applicable to participants across academia, pharmaceutical industry and regulatory agencies interested in expanding their knowledge in cytokine release syndrome.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the cytokine release syndrome (CRS);
2. Discuss the implication of CRS in drug development;
3. Explain the utility of modeling approaches for prediction of CRS;
4. Describe the utility of modeling approaches for estimating CRS mediated DDI.

Requirements to Receive Credit

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Faculty: Yanke Yu, PhD, Distinguished Scientist, employed at Genentech Inc, planned the continuing education documentation for this course and all of the relevant financial relationships listed for this individual have been mitigated.

Planner: Benjamin Colton, PharmD, Section Chief, Clinical Pharmacy Specialists, National Inst of Health, planned the continuing education documentation for this course. He holds stock in GE Healthcare, Pfizer & Merck and all of the relevant financial relationships listed for this individual have been mitigated.

CE Reviewer: Keith Schmidt, PharmD, PhD, Pharmacist, National Cancer Inst, served as the CE Reviewer and has nothing to disclose.

Schedule & Fees

ACCP webinar programs occur several times per year. Registration for the webinars is required but free of charge to all learners.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 5/29/2025

Expiration Date: 5/29/2028

Online Location:

https://accp1.org/Members/Continuing_Education/Clinical-Practice-Webinars/ACCP1/4Continuing_Education/Clinical-Practice-Webinars.aspx